TY - JOUR
T1 - 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis
AU - for the DCVAS Study Group
AU - Grayson, Peter C.
AU - Ponte, Cristina
AU - Suppiah, Ravi
AU - Robson, Joanna C.
AU - Craven, Anthea
AU - Judge, Andrew
AU - Khalid, Sara
AU - Hutchings, Andrew
AU - Luqmani, Raashid A.
AU - Watts, Richard A.
AU - Merkel, Peter A.
AU - Gatenby, Paul
AU - Hill, Catherine
AU - Ranganathan, Dwarakanathan
AU - Kronbichler, Andreas
AU - Blockmans, Daniel
AU - Barra, Lillian
AU - Carette, Simon
AU - Pagnoux, Christian
AU - Dhindsa, Navjot
AU - Fifi-Mah, Aurore
AU - Khalidi, Nader
AU - Liang, Patrick
AU - Milman, Nataliya
AU - Pineau, Christian
AU - Tian, Xinping
AU - Wang, Guochun
AU - Wang, Tian
AU - Zhao, Ming hui
AU - Tesar, Vladimir
AU - Baslund, Bo
AU - Hammam, Nevin
AU - Shahin, Amira
AU - Pirila, Laura
AU - Putaala, Jukka
AU - Hellmich, Bernhard
AU - Henes, Jörg
AU - Lamprecht, Peter
AU - Neumann, Thomas
AU - Schmidt, Wolfgang
AU - Sunderkoetter, Cord
AU - Szekanecz, Zoltan
AU - Danda, Debashish
AU - Das, Siddharth
AU - Gupta, Rajiva
AU - Rajasekhar, Liza
AU - Sharma, Aman
AU - Wagh, Shrikant
AU - Clarkson, Michael
AU - Molloy, Eamonn
N1 - Publisher Copyright:
© 2022 American College of Rheumatology.
PY - 2022/3
Y1 - 2022/3
N2 - Objective: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data-driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1 × 109/liter (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (−3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1), and hematuria (−1). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% confidence interval [95% CI] 77–91%) and the specificity was 99% (95% CI 98–100%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for EGPA demonstrate strong performance characteristics and are validated for use in research.
AB - Objective: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data-driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1 × 109/liter (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (−3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1), and hematuria (−1). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% confidence interval [95% CI] 77–91%) and the specificity was 99% (95% CI 98–100%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for EGPA demonstrate strong performance characteristics and are validated for use in research.
UR - http://www.scopus.com/inward/record.url?scp=85125080532&partnerID=8YFLogxK
U2 - 10.1002/art.41982
DO - 10.1002/art.41982
M3 - Journal articles
C2 - 35106968
AN - SCOPUS:85125080532
SN - 2326-5191
VL - 74
SP - 386
EP - 392
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 3
ER -